Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Add-on amantadine with clonidine for opioid withdrawal symptoms
IRCT20090801002266N15Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- May 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of amantadine, clonidine and buprenorphine in opioid withdrawal and opioid use disorder (OUD) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Subjective Opioid Withdrawal Scale score at day 21. Started May 2021; status: completed.
02
Drugs
amantadineclonidinebuprenorphine
03
Conditions
opioid withdrawalopioid use disorder (OUD)
Beyond the preview
Go deeper on IRCT20090801002266N15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090801002266N15.